Percheron Therapeutics Limited has released a press release.
Appendix 4E and Annual Report
Filed with ASX ·
6ix hasn’t read this filing yet.
Percheron Therapeutics Limited on 6ix
Earlier from Percheron Therapeutics
- Percheron licenses HMBD-002 from Hummingbird Bioscience
- Trading Halt
- Response to ASX Query
- Letter From The Chair and Half Year Accounts
- Topline Six-Month Results From Phase IIb Study of Avicursen
Later from Percheron Therapeutics
- Percheron Therapeutics Limited to Present at the Life Sciences Virtual Investor Forum September 18th
- Quarterly Activities Report and Appendix 4C
- Quarterly Activities/Appendix 4C Cash Flow Report
- Half Yearly Report and Accounts
- Non-renounceable Entitlement Offer
Follow Percheron Therapeutics into a list and get an email when it puts out news.
Follow Percheron Therapeutics